Mamyzin®

Ester of benzylpenicillin for subcutaneous or intramuscular injection

Composition and Presentation:
Mamyzin® is the trade name of penethamate hydriodide an ester of benzylpenicillin. Each clear glass vial contains penethamate hydriodide as an off-white sterile powder for reconstituting using the enclosed water for injection. 5 g and 10 g of penethamate hydriodide are equivalent to 5 million i.u. and 10 million i.u. of benzylpenicillin (penicillin G) respectively.

Actions:
Penethamate hydriodide as an ester is lipophilic and basic. It has a special ability to diffuse through cell membranes securing a rapid and even distribution throughout the tissue of the target organ. It is particularly suitable for the treatment of infections of the mammary, respiratory and uterine tissue.

Pharmacokinetic Properties:
Mamyzin® (penethamate hydriodide) protects and conveys the benzylpenicillin intact to the focus of infection where it is released to exert its bactericidal effect. Unlike the other commonly used parenteral penicillins, Mamyzin® is a salt of a weak base (pKa 8.5), therefore a high proportion of Mamyzin® appears in the plasma and tissue in a nonionised form. It has a special ability to diffuse through cell membranes, endothelia and tissue barriers, to the focus of infection where it is hydrolysed to the therapeutically active benzylpenicillin.

Warning
This product contains an ester of benzylpenicillin. Penicillins and cephalosporins may cause hypersensitivity (allergy) following injection, inhalation, ingestion or skin contact. Do not handle this product if you know you are sensitised, or if you have been advised not to work with such preparations.

Indications:
Mamyzin® is indicated for the treatment of infections caused by gram-positive bacteria that cause mastitis, respiratory infections, footrot and uterine infections.

Mastitis Therapy:
The levels of penicillin in the milk following an injection of Mamyzin® are about 10 times higher than the levels following injection of other benzylpenicillin preparations at an equivalent dose. The pharmacokinetic properties of Mamyzin® ensure penetration of the mammary tissue even in inflamed quarters, with high penicillin concentrations achieved at the site of the infection. These properties make Mamyzin® suitable for systemic penicillin therapy in acute and subacute mastitis.

DIRECTIONS FOR USE
MUST NOT BE injected intravenously.
Suspend 5 g (10 g) of Mamyzin in 15 mL (30 mL) water for injection.
The reconstituted aqueous suspension is stable for 2 days at room temperature and for 1 week when stored in a refrigerator.
General dosage:
10–15 mg per kg bodyweight daily. Repeat dose for 1 to 5 days depending on condition.
Horses, cattle: 5,000 mg daily
Pigs, sheep: 2,500 mg daily
Repeat dose daily for 1–5 days.
For mastitis in lactating dairy cattle: 10 g on day one followed by 5 g on day two, or 5 g daily for 3 days.
The injection is to be in the anterior half of the neck.
In very rare cases anaphylactic shock may occur.

It is an offence for users of this product to cause residues exceeding the relevant MRL in the New Zealand (Maximum Residue Limits of Agricultural Compounds) Food Standards.

WITHHOLDING PERIOD
Meat: Animal producing meat and offal for human consumption must not be sold for slaughter during or within 7 days of the last treatment.
Cattle Milk: Milk intended for sale for human consumption must be discarded during and for not less than 48 hours after the last treatment of 5 g daily dosage and 60 hours after the last treatment of 10 g plus 5 g.
Must not be fed to bobby calves.
Sheep Milk: Milk intended for sale for human consumption must be discarded during and for not less than 35 days following the last treatment.

Storage:
Store below 30°C (room temperature)

Presentation:
Mamyzin® is presented as 5 g of powder in 20 mL vials with 15 mL of water for injection and as 10 g of powder in 50 mL vials with 30 mL of water for injection, 10 vials of each per carton.

Restricted Veterinary Medicine. No. A593.
See www.foodsafety.govt.nz for registration conditions.

Boehringer Ingelheim (N.Z.) Limited
Animal Health Division
Level 1, Unit 9
East Tamaki, Auckland

RESTRICTED VETERINARY MEDICINE
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY